Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 15,653,951.35, representing a significant increase of 122.85% year-over-year[10] - Operating revenue for Q1 2023 reached CNY 48,355,904.46, marking a growth of 40.88% compared to the same period last year[10] - Operating profit for Q1 2023 was CNY 23,917,267.22, compared to CNY 10,692,417.73 in Q1 2022, indicating an increase of about 123.5%[36] - Net profit for Q1 2023 was CNY 18,570,360.41, up from CNY 8,721,887.31 in Q1 2022, reflecting a growth of approximately 112.5%[36] - Basic earnings per share for Q1 2023 were CNY 0.17, compared to CNY 0.11 in Q1 2022, marking a 54.5% increase[36] - Total operating revenue for Q1 2023 reached CNY 48,355,904.46, a significant increase from CNY 34,323,159.94 in Q1 2022, representing a growth of approximately 40.9%[35] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 635,285,442.88, a decrease of 0.21% compared to the end of 2022[10] - Total liabilities decreased to CNY 28,881,772.31 in Q1 2023 from CNY 39,162,782.94 in Q1 2022, a reduction of approximately 26.3%[33] - The total liabilities to total assets ratio decreased to 6.87% from 8.94% year-over-year, indicating improved financial stability[10] - Total equity increased to CNY 554,482,021.79 in Q1 2023, compared to CNY 533,265,013.69 in Q1 2022, representing a growth of about 4.0%[33] - Total current assets amounted to ¥552,277,760.79, slightly down from ¥553,459,283.93 as of December 31, 2022, reflecting a decrease of approximately 0.2%[28] - Total liabilities decreased to ¥43,656,235.96 from ¥56,916,592.99, a reduction of approximately 23.3%[30] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 5,172,226.30, slightly worsening by 0.65% year-over-year[10] - Cash flow from operating activities showed a net outflow of ¥5,172,226.30, slightly worse than the outflow of ¥5,138,733.60 in Q1 2022[39] - Cash inflow from operating activities for Q1 2023 was $53,229,203.64, up from $40,066,632.51 in Q1 2022, representing a 32.5% increase[41] - Total cash outflow from operating activities in Q1 2023 was $62,554,911.79, compared to $45,866,225.11 in Q1 2022, an increase of 36.3%[41] - Investment activities resulted in a net cash outflow of ¥232,794,801.81, compared to a net inflow of ¥8,119,998.69 in Q1 2022[40] Shareholding Structure - The company reported a total shareholding of 51,892,798 shares, representing 56.70% of the total shares outstanding[20] - Major shareholders include Zhou Fang with 21,767,200 shares (23.79%), and Xiao Changjin with 14,486,500 shares (15.83%)[19] - The company has a total of 10 major shareholders, with the top three holding over 44% of the shares[19] - The shareholding structure indicates familial relationships among major shareholders, which may influence governance[20] Research and Development - Research and development expenses for Q1 2023 were CNY 3,304,808.87, up from CNY 2,839,218.06 in Q1 2022, indicating an increase of approximately 16.3%[35] - Research and development expenses increased to ¥2,772,658.63, compared to ¥2,348,390.43 in the same period last year, reflecting a 18% rise[37] Other Key Points - The company has no ongoing litigation or arbitration matters, and no external guarantees or loans were provided during the reporting period[23] - There were no significant related party transactions or other major transactions reported in the quarter[23] - The company confirmed that all previously disclosed commitments are being fulfilled without any breaches[24] - The financial report for the first quarter of 2023 has not been audited[27] - The company did not engage in any share buyback activities during the reporting period[23] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[31] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[36]
新芝生物(430685) - 2023 Q1 - 季度财报